In non-small cell lung cancer (NSCLC), alterations in at least 10 proto-oncogenes have been suggested as potentially “druggable”, with mutation frequencies varying from 1% to 25% for MAP2K1 and KRAS, respectively, according to the population studied.[13] The best algorithm for testing, including sequential versus multiplex assessment of such alterations is still a matter of debate. This evidence concerns the gene MAP2K1 and non-small cell lung carcinoma.